Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients
Status:
Not yet recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
COVID-19, caused by the novel Severe Acute Respiratory Syndrome Corona Virus 2 (SARSCoV-2),
has become a global pandemic. Fortunately, most of the COVID-19 cases confirmed are
categorized as mild for whom home- based symptomatic management with monitoring of clinical
deterioration is recommended. Despite providing symptomatic management, a therapeutic drug
that would limit the course of infection is greatly needed to stop COVID-19 disease
progression. Considering the current SARS-CoV-2 epidemiology and the legitimate rash towards
appropriate therapies, our study seeks to evaluate the safety and efficacy of low dose
aspirin and ivermectin combination therapy in COVID-19 patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Makerere University
Collaborators:
Joint Clinical Research Center Mbarara University of Science and Technology Ministry of Health, Uganda